Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer
- 22 December 2016
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 24 (2) , 130-136
Abstract
Objectives: To study the behavior of specific coagulation factors in different types of non‐metastatic urological cancers, and to identify their possible role as diagnostic and prognostic markers.Methods: This was a prospective controlled study, which included three cancer patient groups and a control group of healthy individuals. The cancer subgroups consisted of renal (n = 44), prostate (n = 56) and bladder cancer (n = 47). We excluded patients receiving anticoagulant therapy, or with significant comorbidity. In all patients, certain coagulation parameters were measured (prothrombin time, international normalized ratio, partial thromboplastin time, D‐dimers, fibrinogen, F1 + 2, thrombin–antithrombin complex). Statistical analysis was carried out to explore the association of hemostasis markers with tumor–nodes–metastasis stage, Gleason score, transitional cell carcinoma grade, Fuhrman grade and prostate‐specific antigen.Results: Our final sample consisted in 58 control patients and 147 patients with urological cancer. We found specific patterns of increased coagulation factors in the different cancers that were statistically significant. Renal cancer showed increased levels of D‐dimers, partial thromboplastin time and fibrinogen. D‐dimers and fibrinogen were increased in prostate cancer; whereas in bladder cancer, only fibrinogen was elevated. Correlations were found between certain factors and tumor stage and grading, with D‐dimers being independently associated with higher tumor grade. Thrombin–antithrombin complex was associated with Gleason score. Furthermore, D‐dimers, fibrinogen and F1 + 2 were associated with higher tumor stages (II–IV).Conclusions: The coagulation pathway seems to be activated in urological malignancies. Specific panels of coagulation factors might play a role as screening or prognostic tools in earlier stages of renal, prostate and bladder cancer. Further research should also focus on their role in the association of cancer with thromboembolic events.Keywords
This publication has 19 references indexed in Scilit:
- Validation of the Preoperative Plasma Fibrinogen Level as a Prognostic Factor in a European Cohort of Patients with Localized Upper Tract Urothelial CarcinomaJournal of Urology, 2014
- Risk of prostate cancer and thrombosis-related factor polymorphismsBiomedical Reports, 2013
- Coagulation and metastasis: what does the experimental literature tell us?British Journal of Haematology, 2013
- Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinomaBJU International, 2012
- High D-dimer levels are associated with poor prognosis in cancer patientsHaematologica, 2012
- Disseminated Intravascular Coagulation with Excessive Fibrinolysis in Prostate Cancer: A Case Series and Review of the LiteratureOncology, 2011
- Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate CancerAmerican Journal of Clinical Pathology, 2010
- TTP-HUS klinikai képét utánzó és heveny veseelégtelenséggel szövődő krónikus DIC hátterében álló metasztatikus prosztatarák: patomechanizmus, differenciáldiagnózis és kezelés egy eset kapcsánMagyar Onkologia, 2010
- D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis StudyJournal of Clinical Oncology, 2009
- Plasma Levels of Prothrombin Fragment F1+2, D-dimer and Prothrombin Time Correlate with Clinical Stage and Lymph Node Metastasis in Operable Gastric Cancer PatientsJapanese Journal of Clinical Oncology, 2008